Current Opinion in Hematology最新文献_第2页

Clonal hematopoiesis of indeterminate potential: recent developments and perspectives.

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-03-11 DOI: 10.1097/MOH.0000000000000870

Meiqi Guo, Yuan Li, Baobing Zhao

{"title":"Clonal hematopoiesis of indeterminate potential: recent developments and perspectives.","authors":"Meiqi Guo, Yuan Li, Baobing Zhao","doi":"10.1097/MOH.0000000000000870","DOIUrl":"https://doi.org/10.1097/MOH.0000000000000870","url":null,"abstract":"Purpose of review: This review encompasses the recently published information on clonal hematopoiesis of indeterminate potential (CHIP) and discusses its future prospects. By announcing advances in the research of CHIP risk factors and related diseases, with the purpose of offering new insights to treat both hematologic and nonhematologic disorders.Recent findings: The majority of studies have shown that CHIP is a common biological condition associated with aging and the incidence of clonal hematopoiesis increases with age. The pathophysiology of blood diseases is projected to be significantly influenced by CHIP. Nevertheless, increasing studies have expanded the application of CHIP to cover nonhematologic diseases such as cardiovascular, renal, liver, and pulmonary diseases. Furthermore, with the fast advancement of genetic testing technology and preventive medicine, the involvement of CHIP in a variety of disorders shows promise as an essential target for preventing disease onset and progression.Summary: CHIP is linked to a variety of illnesses and has a significant influence on an individual's health outlook. Thus, identifying and managing CHIP is critical for improving the clinical results of the individuals concerned.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial introduction.

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-03-01 Epub Date: 2025-01-30 DOI: 10.1097/MOH.0000000000000857

引用次数: 0

Models to study myelodysplastic syndrome and acute myeloid leukaemia. 研究骨髓增生异常综合症和急性髓性白血病的模型。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-03-01 Epub Date: 2024-11-27 DOI: 10.1097/MOH.0000000000000856

Clifford Chao, Isabella G Martinez, Elvin Wagenblast

{"title":"Models to study myelodysplastic syndrome and acute myeloid leukaemia.","authors":"Clifford Chao, Isabella G Martinez, Elvin Wagenblast","doi":"10.1097/MOH.0000000000000856","DOIUrl":"10.1097/MOH.0000000000000856","url":null,"abstract":"Purpose of review: Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematological malignancies characterized by complex genetic alterations, leading to poor clinical outcomes. Despite advances in treatment, there is an urgent need for novel therapeutic approaches. This review outlines recent progress in humanized models of MDS and AML and highlight their role in advancing our understanding of these diseases.Recent findings: Patient derived xenografts (PDXs) were among the first humanized models for studying MDS and AML, allowing researchers to analyze patient-specific cancer properties in vivo . However, they face challenges related to sample availability and consistent engraftment in mice. New methods, including specialized mouse strains and human tissue scaffolds, have been developed to address these issues. Induced pluripotent stem cells (iPSCs) offer the advantage of indefinite expansion and genetic modification, making them valuable for in vitro research, though protocols to enhance their engraftment in vivo are still being refined. Genetically engineered human primary hematopoietic stem and progenitor cells (HSPCs) provide reliable in vivo models with good engraftment in mice, and recent advancements in culture systems and gene-editing techniques are helping to overcome challenges related to ex vivo expansion and genetic modification.Summary: PDXs, iPSCs, and genetically engineered HSPCs are crucial models for the study of MDS and AML. This review discusses strengths, limitations, and recent advancements of these humanized models, which provide insights into human-specific disease biology and therapeutic development.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"87-92"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Red blood cell changes due to cancer and cancer treatments: a narrative review. 癌症和癌症治疗引起的红细胞变化：叙述性回顾。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-03-01 Epub Date: 2025-01-09 DOI: 10.1097/MOH.0000000000000859

Deirdre Finnigan, Omar I Hajjaj, Maha Othman

{"title":"Red blood cell changes due to cancer and cancer treatments: a narrative review.","authors":"Deirdre Finnigan, Omar I Hajjaj, Maha Othman","doi":"10.1097/MOH.0000000000000859","DOIUrl":"10.1097/MOH.0000000000000859","url":null,"abstract":"Purpose of review: To date, there is relatively limited research investigating changes in red blood cells (RBCs), particularly qualitative changes, in cancer patients and cancer patients receiving treatment. These changes may be important in better understanding cancer-associated anemia, which is the most prevalent hematological disorder in cancer patients with wide-ranging implications on patient care and quality of life. This review aims to summarize available evidence regarding qualitative and quantitative changes in RBCs in individuals with cancer prior to treatment and in patients undergoing treatment.Recent findings: The most commonly reported changes in RBCs in cancer patients were increased mean corpuscular volume (MCV) and decreased hemoglobin, RBC count, and hematocrit. There were increased lipid peroxidation products and decreased antioxidants. There were increased polyunsaturated fatty acids (PUFAs) and decreased monounsaturated fatty acids (MUFAs) and saturated fatty acids (FAs). Additionally, RBC shape alterations with various atypical morphologies, membrane structure abnormalities, and impaired fluidity were also reported. These and various other reported findings are discussed in depth.Summary: There are several reported quantitative and qualitative RBC changes in individuals with cancer, with some studies exhibiting conflicting results. Further research is needed to solidify the data and to better understand hematological-associated comorbidities in those patients.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"93-103"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unraveling lipid metabolism for acute myeloid leukemia therapy. 揭示急性髓性白血病治疗中的脂质代谢。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-03-01 Epub Date: 2024-11-25 DOI: 10.1097/MOH.0000000000000853

Cristiana O'Brien, Courtney L Jones

{"title":"Unraveling lipid metabolism for acute myeloid leukemia therapy.","authors":"Cristiana O'Brien, Courtney L Jones","doi":"10.1097/MOH.0000000000000853","DOIUrl":"10.1097/MOH.0000000000000853","url":null,"abstract":"Purpose of review: The aim of this review is to highlight the importance of lipids' intricate and interwoven role in mediating diverse acute myeloid leukemia (AML) processes, as well as potentially novel lipid targeting strategies. This review will focus on new studies of lipid metabolism in human leukemia, particularly highlighting work in leukemic stem cells (LSCs), where lipids were assessed directly as a metabolite.Recent findings: Lipid metabolism is essential to support LSC function and AML survival through diverse mechanisms including supporting energy production, membrane composition, signaling pathways, and ferroptosis. Recent work has highlighted the role of lipid rewiring in metabolic plasticity which can underlie therapy response, the impact of cellular and genetic heterogeneity in AML on lipid metabolism, and the discovery of noncanonical roles of lipid related proteins in AML.Summary: Recent findings around lipid metabolism clearly demonstrates their importance to our understanding and therapeutic targeting of AML. We have only begun to unravel the regulation and utilization of lipids in this disease. Further, understanding the layered dynamics of lipid homeostasis could provide novel opportunities to target lipid metabolism in AML and LSCs with the potential of improving outcomes for patients with AML.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"77-86"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Posttransplant cyclophosphamide: a universal graft versus host disease prophylaxis. 移植后环磷酰胺：一种通用的移植物抗宿主疾病预防疗法。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-03-01 Epub Date: 2024-11-21 DOI: 10.1097/MOH.0000000000000840

Andrea Bacigalupo

{"title":"Posttransplant cyclophosphamide: a universal graft versus host disease prophylaxis.","authors":"Andrea Bacigalupo","doi":"10.1097/MOH.0000000000000840","DOIUrl":"10.1097/MOH.0000000000000840","url":null,"abstract":"Purpose of review: The purpose of this review is to outline current graft versus host disease (GvHD) prophylaxis, in the era of posttransplant cyclophosphamide (PTCY), in patients with malignant and nonmalignant hematologic disorders. The original combination of PTCY with a calcineurin inhibitor (CNI) and mycophenolate (MMF), reported from the Johns Hopkins University in Baltimore, was designed for patients receiving a graft from a donor mismatched at one haplotype, so called haploidentical donor (HAPLO). In the past decade, PTCY has been widely used in HAPLO transplants worldwide, confirming the amazing efficacy of PTCY in preventing GvHD in mismatched grafts.Recent findings: More recently, PTCY is being tested also in grafts from human leukocyte antigen (HLA) identical related or unrelated donors. In the present review we will also answer several open questions, such as: PTCY and cardiac toxicity; PTCY dose; PTCY timing; PTCY and antithymocyte globulin (ATG); engraftment kinetics; infections; PTCY and leukemia relapse; PTCY and HLA identical grafts.Summary: PTCY is currently one of the most effective measures to prevent GvHD, and can be customized in different transplant platforms, together with other immunosuppressive agents. There is place for improvement, and several possible modifications of PTCY dose and schedule can be tested in prospective trials.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"104-108"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142683398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Germline DDX41 mutations in myeloid neoplasms: the current clinical and molecular understanding. 骨髓性肿瘤中的胚系 DDX41 基因突变：目前的临床和分子认识。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-03-01 Epub Date: 2024-11-20 DOI: 10.1097/MOH.0000000000000854

Junichiro Kida, Timothy M Chlon

{"title":"Germline DDX41 mutations in myeloid neoplasms: the current clinical and molecular understanding.","authors":"Junichiro Kida, Timothy M Chlon","doi":"10.1097/MOH.0000000000000854","DOIUrl":"10.1097/MOH.0000000000000854","url":null,"abstract":"Purpose of review: DDX41 mutations are the most common cause of germline predisposition to adult-onset myeloid neoplasms. The unique mutational landscape and clinical features indicate a distinct molecular pathogenesis, but the precise mechanism by which DDX41 mutations cause disease is poorly understood, owing to the multitude of DDX41 functions. In this review, we will update DDX41's known functions, present unique clinical features and treatment considerations, and summarize the current understanding of the molecular pathogenesis of the disease.Recent findings: Large cohort studies have revealed that germline DDX41 variants are heterozygous and predominantly loss-of-function. Acquired mutation of the contralateral DDX41 allele, typically R525H, is present in more than half of patients at disease onset, which occurs after age 50. DDX41 is essential for hematopoiesis and has versatile functions in RNA metabolism and innate immune sensing. Experimental models have suggested that innate immune activation downstream of defects in R-loop resolution and ribosome biogenesis plays a key role in the pathogenesis.Summary: While intensive investigations unveiled a strong genotype-phenotype relationship, the optimal therapeutic approach and long-term outcome are undefined. There is an urgent need to scrutinize the patients at single cell and multiomics level and to advance experimental animal and human models to fully elucidate the molecular pathogenesis.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"67-76"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11781971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Platelets come together, in sweet harmony?! 血小板聚集在一起，在甜蜜的和谐中？

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-12-05 DOI: 10.1097/MOH.0000000000000844

Dianne E van der Wal

引用次数: 0

Platelets and circulating (tumor) cells: partners in promoting metastatic cancer. 血小板和循环（及肿瘤）细胞：促进癌症转移的伙伴。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-11-21 DOI: 10.1097/MOH.0000000000000852

Deepa Gautam, Emily M Clarke, Harvey G Roweth, Margaret R Smith, Elisabeth M Battinelli

{"title":"Platelets and circulating (tumor) cells: partners in promoting metastatic cancer.","authors":"Deepa Gautam, Emily M Clarke, Harvey G Roweth, Margaret R Smith, Elisabeth M Battinelli","doi":"10.1097/MOH.0000000000000852","DOIUrl":"10.1097/MOH.0000000000000852","url":null,"abstract":"Purpose of review: Despite being discovered decades ago, metastasis remains a formidable challenge in cancer treatment. During the intermediate phase of metastasis, tumor cells detach from primary tumor or metastatic sites and travel through the bloodstream and lymphatic system to distant tissues. These tumor cells in the circulation are known as circulating tumor cells (CTCs), and a higher number of CTCs has been linked to poor prognoses in various cancers. The blood is an inhospitable environment for any foreign cells, including CTCs, as they face numerous challenges, such as the shear stress within blood vessels and their interactions with blood and immune cells. However, the exact mechanisms by which CTCs survive the hostile conditions of the bloodstream remain enigmatic. Platelets have been studied for their interactions with tumor cells, promoting their survival, growth, and metastasis. This review explores the latest clinical methods for enumerating CTCs, recent findings on platelet-CTC crosstalk, and current research on antiplatelet therapy as a potential strategy to inhibit metastasis, offering new therapeutic insights.Recent findings: Laboratory and clinical data have provided insights into the role of platelets in promoting CTC survival, while clinical advancements in CTC enumeration offer improved prognostic tools.Summary: CTCs play a critical role in metastasis, and their interactions with platelets aid their survival in the hostile environment of the bloodstream. Understanding this crosstalk offers insights into potential therapeutic strategies, including antiplatelet therapy, to inhibit metastasis and improve cancer treatment outcomes.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"52-60"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of selective serotonin reuptake inhibitors on platelet functions: a literature review. 选择性血清素再摄取抑制剂对血小板功能的影响：文献综述。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-10-09 DOI: 10.1097/MOH.0000000000000847

Antoine Mokhtarian, Virginie Siguret, Georges Jourdi

{"title":"Effects of selective serotonin reuptake inhibitors on platelet functions: a literature review.","authors":"Antoine Mokhtarian, Virginie Siguret, Georges Jourdi","doi":"10.1097/MOH.0000000000000847","DOIUrl":"10.1097/MOH.0000000000000847","url":null,"abstract":"Purpose of review: Many epidemiological studies have evidenced an increased bleeding risk associated with selective serotonin reuptake inhibitors (SSRIs), yet the underlying mechanisms remain unclear. This review summarizes data on SSRIs' effects on platelet functions assessed with assays used in clinical practice and highlights the areas that deserve further investigation.Recent findings: Conflicting results of SSRI effects on platelet aggregation were observed irrespectively of the agonist used, the antidepressant drug or the study type. Alike, discrepant results were reported with flow-cytometry-based assays assessing either platelet surface glycoprotein levels, integrin activation, agonist-induced secretion of intraplatelet granule content or membrane anionic phospholipid exposure. Other tests may have detected a platelet function defect in SSRIs samples, however, results were largely inconsistent.Summary: Critical literature examination unveils very low certainty of evidence on potential SSRI effect on platelet functions. Findings are often inconsistent even when similar methods are used, most likely because of differences in study design, included patients (age, comorbid conditions), SSRIs' type and dose, uncontrolled confounding factors, and statistical analysis power. Further studies are needed to disentangle any intrinsic antiplatelet effect of SSRIs and the multiple confounding factors, mainly the depression control itself and the degree of platelet SERT inhibition.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"22-33"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142481401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0